{ "meta": { "data_length": 1, "message": "Statement id stmt:hse:00401:b:0 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Ahse%3A00401%3Ab%3A0", "status": "success", "status_code": 200, "timestamp_elapsed": 0.001965, "timestamp_received": "2026-10-17T00:04:45.995568+00:00Z", "timestamp_returned": "2026-10-17T00:04:45.997533+00:00Z", "trace_id": "1883d7be-502f-4a2b-b864-1b2b3a21d500" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:hse:00401:b:0", "type": "Statement", "description": "The Republic of Ireland's Health Service Executive (HSE) has approved alectinib for reimbursement as a monotherapy treatment option for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). This indication is specifically for patients whose tumors have been historically confirmed to be NSCLC with an ALK rearrangement identified by an approved and validated test method.", "contributions": [ { "id": "ctrb:vanallenlab:2024-01-16:0", "type": "Contribution", "description": "Adding HSE approvals for reimbursement to database", "date": "2024-01-16", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:hse:2019-06-01:0", "type": "Contribution", "description": "Indication approved for reimbursement.", "date": "2019-06-01", "contributor": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." } } ], "reportedIn": [ { "id": "doc:hse:00401", "type": "Document", "documentType": "Regulatory approval", "name": "Alectinib Monotherapy. NCCP National SACT Regimen. HSE.", "title": null, "aliases": [], "description": "Alectinib Monotherapy, 2025, version number 6, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6910/401_V6_Alectinib.pdf", "urls": [ "https://healthservice.hse.ie/documents/6910/401_V6_Alectinib.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." }, "description": "The organization that published this document." }, { "name": "company", "value": "", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": null, "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": null, "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-05-13", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:22", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C2926", "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Non-Small+Cell+Lung+Cancer+%28NSCLC%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C2926", "code": "C2926", "name": "Lung Non-Small Cell Carcinoma", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2926" ] } }, "objectTherapeutic": { "id": "tx:ncit:C101790", "conceptType": "Therapy", "name": "Alectinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1727455", "code": "1727455", "name": "alectinib", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1727455" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:35604657", "code": "35604657", "name": "alectinib", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/35604657" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "ALK inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C101790", "code": "C101790", "name": "Alectinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C101790" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:8", "present": true, "subject": { "id": "bmkr:8", "type": "CategoricalVariant", "name": "v::ALK", "constraints": [ { "type": "AdjacencyConstraint", "orderKnown": false, "adjoinedElements": [ { "id": "gene:hgnc:427", "conceptType": "Gene", "name": "ALK", "primaryCoding": { "id": "coding:hgnc:427", "code": "HGNC:427", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000171094", "code": "ENSG00000171094", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000171094" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:238", "code": "238", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/238" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004304.5", "code": "NM_004304.5", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5" ] } } ] }, { "type": "UnspecifiedElement" } ] } ], "extensions": [ { "name": "biomarker_type", "value": "Gene fusion" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:hse:00401:b", "type": "Indication", "description": "As monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).", "contributions": [ { "id": "ctrb:vanallenlab:2024-01-16:0", "type": "Contribution", "description": "Adding HSE approvals for reimbursement to database", "date": "2024-01-16", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:hse:2019-06-01:0", "type": "Contribution", "description": "Indication approved for reimbursement.", "date": "2019-06-01", "contributor": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." } } ], "reportedIn": [ { "id": "doc:hse:00401", "type": "Document", "documentType": "Regulatory approval", "name": "Alectinib Monotherapy. NCCP National SACT Regimen. HSE.", "title": null, "aliases": [], "description": "Alectinib Monotherapy, 2025, version number 6, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6910/401_V6_Alectinib.pdf", "urls": [ "https://healthservice.hse.ie/documents/6910/401_V6_Alectinib.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." }, "description": "The organization that published this document." }, { "name": "company", "value": "", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": null, "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": null, "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-05-13", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." }, { "name": "reimbursement_scheme", "value": "CDS", "description": "Current scheme used to reimburse indication." }, { "name": "reimbursement_comment", "value": null, "description": "More details about the current reimbursement scheme(s)." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }